DRIO - DarioHealth Corp Stock Price, Fair Value and News

1.90USD+0.02 (+1.06%)Delayed

Market Summary

USD1.90+0.02

Delayed

1.06%

DRIO Stock Price

View Fullscreen

DRIO RSI Chart

DRIO Valuation

Market Cap

56.9M

Price/Earnings (Trailing)

-1.06

Price/Sales (Trailing)

2.99

EV/EBITDA

-0.9

Price/Free Cashflow

-1.45

DRIO Price/Sales (Trailing)

DRIO Profitability

Operating Margin

85.74%

EBT Margin

-292.52%

Return on Equity

-68.92%

Return on Assets

-39.26%

Free Cashflow Yield

-69.12%

DRIO Fundamentals

DRIO Revenue

Revenue (TTM)

19.0M

Rev. Growth (Yr)

-18.51%

Rev. Growth (Qtr)

59.24%

DRIO Earnings

Earnings (TTM)

-53.8M

Earnings Growth (Yr)

44.05%

Earnings Growth (Qtr)

49.77%

Breaking Down DRIO Revenue

Last 7 days

21.0%

Last 30 days

57.0%

Last 90 days

-19.1%

Trailing 12 Months

-49.6%

How does DRIO drawdown profile look like?

DRIO Financial Health

Current Ratio

2.95

Debt/Equity

0.31

Debt/Cashflow

-1.58

DRIO Investor Care

Shares Dilution (1Y)

13.51%

Diluted EPS (TTM)

1.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	19.0M	0	0	0
2023	26.7M	26.6M	23.5M	20.4M
2022	25.0M	25.9M	26.9M	27.7M
2021	9.5M	13.0M	16.6M	20.5M
2020	7.0M	7.1M	7.3M	7.6M
2019	7.9M	7.5M	7.5M	7.6M
2018	5.9M	6.8M	7.3M	7.4M
2017	3.2M	3.8M	4.4M	5.2M
2016	1.3M	1.8M	2.3M	2.8M
2015	244.0K	437.0K	630.0K	823.0K
2014	0	0	0	51.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of DarioHealth Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 06, 2024	shaked yoav	acquired	-	-	90,000	-
Mar 06, 2024	stern adam k	acquired	-	-	70,000	-
Mar 06, 2024	ben-david zvi	acquired	-	-	400,000	chief financial officer
Mar 06, 2024	kaplan jon h.	acquired	-	-	70,000	-
Mar 06, 2024	mcgrath dennis m	acquired	-	-	80,000	-
Mar 06, 2024	matheis dennis	acquired	-	-	70,000	-
Mar 06, 2024	karah hila	acquired	-	-	70,000	-
Mar 06, 2024	raphael erez	acquired	-	-	800,000	chief executive officer
Jan 13, 2023	raphael erez	sold	-7,449	6.2075	-1,200	chief executive officer
Dec 21, 2022	mcgrath dennis m	sold	-39,205	3.9714	-9,872	-

Which funds bought or sold DRIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-14,318	115,298	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	2.98	-15,209	165,935	-%
May 15, 2024	Royal Bank of Canada	added	13,662	202,000	204,000	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-19,620	-	-%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-43.67	-4,010,610	4,027,820	0.23%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-2.85	-1,057	6,736	-%
May 15, 2024	Phoenix Holdings Ltd.	unchanged	-	-480,577	1,807,140	0.03%
May 15, 2024	Steward Partners Investment Advisory, LLC	reduced	-41.35	-3,366	3,672	-%
May 15, 2024	Appian Way Asset Management LP	added	0.88	-233,367	2,041,240	0.54%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-26.3	-14,821	28,213	-%

Are Funds Buying or Selling DRIO?

Are funds buying DRIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DRIO

No. of Funds

Unveiling DarioHealth Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	9.9%	2,761,140	SC 13G/A
Feb 06, 2024	y.d. more investments ltd	4.73%	1,288,518	SC 13G/A
Sep 08, 2023	kershner trading americas,llc	3.87%	1,053,024	SC 13G/A
Feb 14, 2023	phoenix holdings ltd.	5.22%	1,341,027	SC 13G/A
Feb 14, 2023	collaborative holdings management lp	0%	0	SC 13G/A
Feb 14, 2023	nantahala capital management, llc	9.9%	2,576,318	SC 13G/A
Feb 13, 2023	y.d. more investments ltd	5.91%	1,518,025	SC 13G/A
Feb 13, 2023	clal insurance enterprises holdings ltd	4.2%	1	SC 13G/A
May 18, 2022	kershner trading americas,llc	5.6%	0	SC 13G
Mar 14, 2022	phoenix holdings ltd.	6.12%	1,341,027	SC 13G/A

Recent SEC filings of DarioHealth Corp

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 08, 2024	EFFECT	EFFECT
May 03, 2024	S-3/A	S-3/A
May 01, 2024	DEF 14A	DEF 14A
Apr 22, 2024	8-K	Current Report
Apr 22, 2024	S-3	S-3
Apr 19, 2024	424B3	Prospectus Filed
Apr 19, 2024	8-K	Current Report
Apr 19, 2024	PRE 14A	PRE 14A
Apr 05, 2024	8-K	Current Report

Peers (Alternatives to DarioHealth Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

DarioHealth Corp News

Latest updates

DarioHealth Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	59.2%	5,758,000	3,616,000	3,518,000	6,152,000	7,066,000	6,809,000	6,605,000	6,183,000	8,059,000	6,028,000	5,629,000	5,261,000	3,595,000	2,080,000	2,042,000	1,787,000	1,667,000	1,798,000	1,868,000	1,651,000	2,242,000
Gross Profit	1742.4%	2,432,000	132,000	610,000	2,074,000	3,168,000	2,732,000	1,800,000	1,138,000	3,985,000	548,000	826,000	1,508,000	1,081,000	549,000	549,000	636,000	779,000	840,000	873,000	326,000	558,000
Operating Expenses	41.4%	20,287,000	14,347,000	16,156,000	16,094,000	15,576,000	11,742,000	16,373,000	18,493,000	19,857,000	22,213,000	23,325,000	19,511,000	15,408,000	9,613,000	7,151,000	4,759,000	10,893,000	5,021,000	3,672,000	5,688,000	5,921,000
S&GA Expenses	-100.0%	-	5,529,000	4,128,000	4,412,000	4,071,000	3,040,000	3,999,000	5,059,000	4,395,000	4,667,000	7,123,000	6,121,000	5,621,000	3,297,000	2,562,000	1,326,000	5,571,000	1,858,000	948,000	1,704,000	973,000
R&D Expenses	58.3%	6,642,000	4,196,000	5,665,000	5,222,000	5,165,000	4,782,000	4,803,000	4,137,000	5,927,000	5,316,000	5,506,000	3,742,000	2,655,000	1,423,000	954,000	825,000	1,231,000	840,000	859,000	991,000	1,002,000
EBITDA Margin	0.1%	-2.69	-2.70	-2.36	-2.08	-2.13	-2.37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-1.0%	986,000	996,000	991,000	972,000	1,072,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-Infinity%	-1,994,000	-	-	-	-	3,000	-	1,000	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	35.5%	-9,169,000	-14,221,000	-15,732,000	-16,585,000	-12,825,000	-12,614,000	-15,632,000	-18,027,000	-	-21,554,000	-22,444,000	-17,765,000	-	-	-	-	-	-	-	-	-
EBT Margin	-0.3%	-2.93	-2.92	-2.45	-2.16	-2.22	-2.45	-2.89	-3.08	-3.07	-3.74	-1.78	-2.27	-3.10	-	-	-	-	-	-	-	-
Net Income	49.8%	-7,175,000	-14,285,000	-15,732,000	-16,585,000	-12,825,000	-12,617,000	-15,632,000	-18,028,000	-15,916,000	-21,586,000	-22,444,000	-17,765,000	-14,966,000	-8,997,000	-6,550,000	-4,006,000	-9,892,000	-4,173,000	-2,805,000	-5,382,000	-5,376,000
Net Income Margin	3.3%	-2.82	-2.92	-2.45	-2.17	-2.22	-2.25	-2.65	-3.01	-3.11	-3.74	-3.87	-3.72	-3.63	-	-	-	-	-	-	-	-
Free Cashflow	-77.3%	-13,166,000	-7,424,000	-8,926,000	-9,782,000	-4,831,000	-7,984,000	-10,869,000	-11,274,000	-18,160,000	-15,204,000	-12,531,000	-12,335,000	-10,600,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	42.1%	137	96.00	107	117	108	119	126	137	127	101	117	131	124	35.00	41.00	17.00	20.00	25.00	9.00	12.00	11.00
Current Assets	10.9%	53.00	47.00	56.00	66.00	55.00	66.00	72.00	82.00	71.00	46.00	59.00	72.00	88.00	34.00	40.00	16.00	18.00	23.00	7.00	11.00	10.00
Cash Equivalents	-4.8%	35.00	37.00	44.00	53.00	39.00	49.00	57.00	68.00	56.00	36.00	51.00	64.00	81.00	29.00	37.00	13.00	16.00	21.00	5.00	8.00	7.00
Inventory	-2.9%	5.00	5.00	5.00	6.00	7.00	8.00	8.00	8.00	8.00	6.00	4.00	5.00	5.00	2.00	2.00	1.00	1.00	1.00	1.00	2.00	2.00
Net PPE	58.5%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Goodwill	37.9%	57.00	42.00	42.00	42.00	42.00	42.00	42.00	42.00	42.00	42.00	39.00	39.00	25.00	-	-	-	-	-	-	-	-
Current Liabilities	42.5%	18.00	12.00	8.00	8.00	18.00	19.00	12.00	13.00	13.00	14.00	13.00	13.00	12.00	7.00	6.00	5.00	4.00	5.00	4.00	6.00	7.00
Long Term Debt	-0.3%	25.00	25.00	29.00	29.00	17.00	18.00	24.00	23.00	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	0%	4.00	4.00	-	-	-	9.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	25.00	29.00	29.00	17.00	18.00	24.00	23.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	34.2%	78.00	58.00	68.00	78.00	72.00	80.00	89.00	100	114	86.00	104	118	112	28.00	35.00	12.00	15.00	19.00	4.00	6.00	4.00
Retained Earnings	-2.6%	-358	-349	-333	-316	-298	-285	-272	-256	-238	-222	-199	-177	-158	-143	-133	-126	-121	-110	-102	-100	-94.63
Additional Paid-In Capital	7.1%	437	408	402	395	371	366	362	356	353	308	304	295	271	171	169	138	137	129	107	106	98.00
Shares Outstanding	8.3%	29.00	27.00	27.00	27.00	26.00	26.00	23.00	22.00	20.00	17.00	16.00	16.00	14.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	98.00	-	-	-	132	-	-	-	308	-	-	-	26.00	-	-	-	20.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-78.6%	-13,110	-7,341	-8,645	-9,636	-4,757	-7,941	-10,695	-11,115	-18,094	-15,136	-12,435	-12,306	-10,532	-6,760	-3,792	-2,639	-4,545	-2,852	-3,382	-5,502	-3,989
Cashflow From Investing	-10565.1%	-8,852	-83.00	-281	4,179	-4,362	-59.00	-174	-159	-181	-444	-97.00	-5,053	-2,540	-1,549	-30.00	-15.00	-28.00	-26.00	-15.00	-27.00	-45.00
Cashflow From Financing	-	20,206	-	204	19,438	-1,389	265	-	23,652	38,023	-	-	55.00	65,711	-	27,548	-	-	18,689	-	6,558	-
Buy Backs	-	-	-	-	-	-	-	-	134	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DRIO Income Statement

2024-03-31

INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenues	$ 5,758	$ 7,066
Total cost of revenues	3,326	3,898
Gross profit	2,432	3,168
Operating expenses:
Research and development	6,642	5,165
Sales and marketing	6,910	6,340
General and administrative	6,735	4,071
Total operating expenses	20,287	15,576
Operating loss	17,855	12,408
Total financial expenses (income), net	(8,686)	417
Loss before taxes	9,169	12,825
Income Tax	1,994
Net loss	7,175	12,825
Other comprehensive loss:
Deemed dividend	2,034
Net loss attributable to common shareholders	$ 9,209	$ 12,825
Net loss per share:
Basic net loss per share of common stock	$ 0.20	$ 0.45
Diluted net loss per share of common stock	$ 0.20	$ 0.45
Weighted average number of Common Stock used in computing basic net loss per share	34,442,578	27,570,013
Weighted average number of Common Stock used in computing diluted net loss per share	34,442,578	27,570,013
Services
Total revenues	$ 4,160	$ 5,256
Total cost of revenues	965	1,477
Consumer hardware
Total revenues	1,598	1,809
Total cost of revenues	1,198	1,340
Amortization of acquired intangible assets
Total cost of revenues	$ 1,163	$ 1,081

DRIO Balance Sheet

2024-03-31

INTERIM CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 34,367	$ 36,797
Short-term restricted bank deposits	971	292
Trade receivables, net	7,885	3,155
Inventories	4,916	5,062
Other accounts receivable and prepaid expenses	4,370	2,024
Total current assets	52,509	47,330
NON-CURRENT ASSETS:
Deposits	6	6
Operating lease right of use assets	1,813	967
Long-term assets	138	143
Property and equipment, net	1,425	899
Intangible assets, net	23,646	5,404
Goodwill	57,427	41,640
Total non-current assets	84,455	49,059
Total assets	136,964	96,389
CURRENT LIABILITIES:
Trade payables	4,249	1,131
Deferred revenues	1,791	997
Operating lease liabilities	920	111
Other accounts payable and accrued expenses	6,888	6,300
Current maturity of long term loan	3,954	3,954
Total current liabilities	17,802	12,493
NON-CURRENT LIABILITIES
Operating lease liabilities	1,053	885
Long-term loan	24,508	24,591
Warrant liability	15,516	240
Other long-term liabilities	52	36
Total non-current liabilities	41,129	25,752
STOCKHOLDERS' EQUITY
Common stock of $0.0001 par value - authorized: 160,000,000 shares; issued and outstanding: 29,439,740 and 27,191,849 shares on March 31, 2024 and December 31, 2023, respectively	3	3
Preferred stock of $0.0001 par value - authorized: 5,000,000 shares; issued and outstanding: 41,381 and 18,959 shares on March 31, 2024 and December 31, 2023, respectively
Additional paid-in capital	436,600	407,502
Accumulated deficit	(358,570)	(349,361)
Total stockholders' equity	78,033	58,144
Total liabilities and stockholders' equity	$ 136,964	$ 96,389

About DarioHealth Corp

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its user-centric multi-chronic condition digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Move to address most common MSK conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

CEO	Mr. Erez Raphael
WEBSITE	dariohealth.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	241

DarioHealth Corp Frequently Asked Questions

What is the ticker symbol for DarioHealth Corp? What does DRIO stand for in stocks?

DRIO is the stock ticker symbol of DarioHealth Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of DarioHealth Corp (DRIO)?

As of Fri May 17 2024, market cap of DarioHealth Corp is 56.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DRIO stock?

You can check DRIO's fair value in chart for subscribers.

What is the fair value of DRIO stock?

You can check DRIO's fair value in chart for subscribers. The fair value of DarioHealth Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of DarioHealth Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DRIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is DarioHealth Corp a good stock to buy?

The fair value guage provides a quick view whether DRIO is over valued or under valued. Whether DarioHealth Corp is cheap or expensive depends on the assumptions which impact DarioHealth Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DRIO.

What is DarioHealth Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, DRIO's PE ratio (Price to Earnings) is -1.06 and Price to Sales (PS) ratio is 2.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DRIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on DarioHealth Corp's stock?

In the past 10 years, DarioHealth Corp has provided -0.437 (multiply by 100 for percentage) rate of return.